Improved Statistical Modeling of Tumor Growth and Treatment Effect in Preclinical Animal Studies with Highly Heterogeneous Responses In Vivo

Purpose: Preclinical tumor growth experiments often result in heterogeneous datasets that include growing, regressing, or stable growth profiles in the treatment and control groups. Such confounding intertumor variability may mask the true treatment effects especially when less aggressive treatment alternatives are being evaluated. Experimental design: We developed a statistical modeling approach in which the growing and poorly growing tumor categories were automatically detected by means of an expectation-maximization algorithm coupled within a mixed-effects modeling framework. The framework is implemented and distributed as an R package, which enables model estimation and statistical inference, as well as statistical power and precision analyses. Results: When applied to four tumor growth experiments, the modeling framework was shown to (i) improve the detection of subtle treatment effects in the presence of high within-group tumor variability; (ii) reveal hidden tumor subgroups associated with established or novel biomarkers, such as ERβ expression in a MCF-7 breast cancer model, which remained undetected with standard statistical analysis; (iii) provide guidance on the selection of sufficient sample sizes and most informative treatment periods; and (iv) offer flexibility to various cancer models, experimental designs, and treatment options. Model-based testing of treatment effect on the tumor growth rate (or slope) was shown as particularly informative in the preclinical assessment of treatment alternatives based on dietary interventions. Conclusions: In general, the modeling framework enables identification of such biologically significant differences in tumor growth profiles that would have gone undetected or had required considerably higher number of animals when using traditional statistical methods. Clin Cancer Res; 18(16); 4385–96. ©2012 AACR.

[1]  Begg Ac,et al.  Analysis of growth delay data: potential pitfalls. , 1980 .

[2]  Elisabeth Dévière,et al.  Analyzing linguistic data: a practical introduction to statistics using R , 2009 .

[3]  Niina M Saarinen,et al.  Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF‐7 breast cancer xenografts and carcinogen‐induced mammary tumors in rats , 2008, International journal of cancer.

[4]  Kathylynn Saboda,et al.  Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model , 2006, Molecular Cancer Therapeutics.

[5]  Yasushi Okuno,et al.  Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. , 2010, Cancer research.

[6]  Niina M Saarinen,et al.  Enterolactone inhibits the growth of 7,12-dimethylbenz(a)anthracene-induced mammary carcinomas in the rat. , 2002, Molecular cancer therapeutics.

[7]  George Sgouros,et al.  Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. , 2003, Cancer research.

[8]  Hong-Bin Fang,et al.  Hierarchical Models for Tumor Xenograft Experiments in Drug Development , 2004, Journal of biopharmaceutical statistics.

[9]  David Opolon,et al.  Combined effects of docetaxel and angiostatin gene therapy in prostate tumor model. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  Daniel Normolle,et al.  Bayesian Hierarchical Changepoint Methods in Modeling the Tumor Growth Profiles in Xenograft Experiments , 2010, Clinical Cancer Research.

[11]  Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments. , 2005, Statistics in medicine.

[12]  Daniel F. Heitjan,et al.  Biology, Models, and the Analysis of Tumor Xenograft Experiments , 2011, Clinical Cancer Research.

[13]  Hua Liang,et al.  Modeling antitumor activity by using a non-linear mixed-effects model. , 2004, Mathematical biosciences.

[14]  Valerie Speirs,et al.  ERβ1 represses FOXM1 expression through targeting ERα to control cell proliferation in breast cancer. , 2011, The American journal of pathology.

[15]  Hua Liang,et al.  Modeling Antitumor Activity in Xenograft Tumor Treatment , 2005, Biometrical journal. Biometrische Zeitschrift.

[16]  Linlin Lu,et al.  Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells , 2009, Cancer Chemotherapy and Pharmacology.

[17]  S. Robinson,et al.  Reversal of the antitumor effects of tamoxifen by progesterone in the 7,12-dimethylbenzanthracene-induced rat mammary carcinoma model. , 1987, Cancer research.

[18]  M. Plummer,et al.  CODA: convergence diagnosis and output analysis for MCMC , 2006 .

[19]  Hong-Bin Fang,et al.  Small‐Sample Inference for Incomplete Longitudinal Data with Truncation and Censoring in Tumor Xenograft Models , 2002, Biometrics.

[20]  Fang Li,et al.  In vivo bioluminescence imaging monitoring of hypoxia-inducible factor 1alpha, a promoter that protects cells, in response to chemotherapy. , 2008, AJR. American journal of roentgenology.

[21]  Austin F. Frank,et al.  Analyzing linguistic data: a practical introduction to statistics using R , 2010 .

[22]  Alexander Kamb,et al.  What's wrong with our cancer models? , 2005, Nature Reviews Drug Discovery.

[23]  Niina M Saarinen,et al.  Flaxseed attenuates the tumor growth stimulating effect of soy protein in ovariectomized athymic mice with MCF‐7 human breast cancer xenografts , 2006, International journal of cancer.

[24]  A. Begg,et al.  Analysis of growth delay data: potential pitfalls. , 1980, The British journal of cancer. Supplement.

[25]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[26]  J. Maris,et al.  The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  Tero Aittokallio,et al.  Dealing with missing values in large-scale studies: microarray data imputation and beyond , 2010, Briefings Bioinform..

[28]  C. Labrie,et al.  Effects of the antiestrogen EM-800 (SCH 57050) and cyclophosphamide alone and in combination on growth of human ZR-75-1 breast cancer xenografts in nude mice. , 1999, Cancer research.

[29]  Johan Hartman,et al.  Estrogen Receptor β Inhibits Angiogenesis and Growth of T47D Breast Cancer Xenografts , 2006 .

[30]  Heidi L. Weiss,et al.  Low Levels of Estrogen Receptor β Protein Predict Resistance to Tamoxifen Therapy in Breast Cancer , 2004, Clinical Cancer Research.

[31]  D. Heitjan,et al.  Statistical analysis of in vivo tumor growth experiments. , 1993, Cancer research.

[32]  G. Verbeke,et al.  A Linear Mixed-Effects Model with Heterogeneity in the Random-Effects Population , 1996 .

[33]  Andrew Gelman,et al.  Data Analysis Using Regression and Multilevel/Hierarchical Models , 2006 .

[34]  Johan Hartman,et al.  Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. , 2006, Cancer research.

[35]  P. G. Reeves,et al.  AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. , 1993, The Journal of nutrition.

[36]  M. Gleave,et al.  Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen‐independent progression , 2011, The Prostate.